Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,387 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00982488 | Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia(START rollover) | completed | Phase 2 | 238 | Bristol-Myers SquibbINDUSTRY | 24 | Jan 22, 2016 | clinicaltrials |
| NCT01985893 | Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer(THOR) | withdrawn | Phase 2 | 0 | Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V. |
| 1 |
| Jan 14, 2016 |
| clinicaltrials |
| NCT01257360 | Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)(NEO-RIT) | unknown | Phase 2 | 59 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 1 | Jan 13, 2016 | clinicaltrials |
| NCT00718523 | Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer | terminated | Phase 2 | 170 | Translational Research in OncologyOTHER | 8 | Jan 12, 2016 | clinicaltrials |
| NCT00719212 | Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer | completed | Phase 2 | 61 | Translational Research in OncologyOTHER | 7 | Jan 11, 2016 | clinicaltrials |
| NCT01185847 | A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | Hoffmann-La RocheINDUSTRY | 7 | Jan 1, 2016 | clinicaltrials |
| NCT01028222 | A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation(TEAM) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 30, 2015 | clinicaltrials |
| NCT00618982 | Sorafenib Dose Escalation in Renal Cell Carcinoma | completed | Phase 2 | 83 | BayerINDUSTRY | 5 | Dec 24, 2015 | clinicaltrials |
| NCT00031954 | Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | 105 | AGO Study GroupOTHER | 1 | Dec 23, 2015 | clinicaltrials |
| NCT00412776 | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 165 | Sesen Bio, Inc.INDUSTRY | 18 | Dec 23, 2015 | clinicaltrials |
| NCT01263886 | Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer(DISRUPT) | completed | Phase 2 | 176 | SanofiINDUSTRY | 13 | Dec 21, 2015 | clinicaltrials |
| NCT01332656 | Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel(OPSALIN) | completed | Phase 2 | 154 | SanofiINDUSTRY | 10 | Dec 21, 2015 | clinicaltrials |
| NCT01583816 | Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions | completed | Phase 2 | 218 | Spirig Pharma Ltd.INDUSTRY | 2 | Dec 15, 2015 | clinicaltrials |
| NCT01880437 | A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome | terminated | Phase 2 | 38 | Hoffmann-La RocheINDUSTRY | 3 | Dec 15, 2015 | clinicaltrials |
| NCT01360840 | EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer(PERSEUS) | completed | Phase 2 | 180 | EMD SeronoINDUSTRY | 12 | Dec 14, 2015 | clinicaltrials |
| NCT01056341 | Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy | completed | Phase 2 / Phase 3 | 512 | Pierre Fabre DermatologyINDUSTRY | 16 | Dec 10, 2015 | clinicaltrials |
| NCT00188136 | Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML) | completed | Phase 2 | 32 | University Hospital Carl Gustav CarusOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00512980 | PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma | terminated | Phase 2 | — | University of CologneOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00807300 | Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma(CEAL) | completed | Phase 2 | 77 | University of MagdeburgOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT01709162 | Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma | terminated | Phase 2 | 31 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 30, 2015 | clinicaltrials |
| NCT00967330 | A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma | completed | Phase 2 | 182 | Hoffmann-La RocheINDUSTRY | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00157209 | Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer) | completed | Phase 2 | 171 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Nov 18, 2015 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT01187303 | Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) | completed | Phase 2 | 28 | University of CologneOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT00560235 | Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors | completed | Phase 1 / Phase 2 | 138 | PfizerINDUSTRY | 11 | Oct 28, 2015 | clinicaltrials |
| NCT00548704 | A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines | completed | Phase 2 / Phase 3 | 57 | Valerio TherapeuticsINDUSTRY | 5 | Oct 21, 2015 | clinicaltrials |
| NCT00960115 | Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy | completed | Phase 1 / Phase 2 | 178 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 21, 2015 | clinicaltrials |
| NCT01350115 | Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) | completed | Phase 2 | 10 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 19, 2015 | clinicaltrials |
| NCT00437073 | Brain Metastases In ErbB2-Positive Breast Cancer | terminated | Phase 2 | 22 | GlaxoSmithKlineINDUSTRY | 11 | Oct 15, 2015 | clinicaltrials |
| NCT00561990 | Nimotuzumab in Adults With Pancreatic Cancer | completed | Phase 2 / Phase 3 | 188 | Oncoscience AGINDUSTRY | 1 | Oct 15, 2015 | clinicaltrials |
| NCT00612664 | Phase II, 2nd Line Melanoma - RAND Monotherapy | completed | Phase 2 | 158 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 12, 2015 | clinicaltrials |
| NCT01872078 | A Study of AZD4901 in Females With Polycystic Ovary Syndrome | completed | Phase 2 | 67 | AstraZenecaINDUSTRY | 3 | Oct 12, 2015 | clinicaltrials |
| NCT00633789 | Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types | completed | Phase 2 | 597 | Bristol-Myers SquibbINDUSTRY | 9 | Oct 9, 2015 | clinicaltrials |
| NCT01295307 | Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)(BRIDGE) | completed | Phase 2 | 86 | Technische Universität DresdenOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01521533 | NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma | completed | Phase 2 | 28 | TME Pharma AGINDUSTRY | 4 | Oct 6, 2015 | clinicaltrials |
| NCT00229697 | Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study | completed | Phase 2 | 317 | AstraZenecaINDUSTRY | 12 | Oct 5, 2015 | clinicaltrials |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)(LUCID) | terminated | Phase 2 | 627 | BiogenINDUSTRY | 23 | Oct 2, 2015 | clinicaltrials |
| NCT00395252 | Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer(ATIP) | completed | Phase 2 | 76 | Carmen Schade-BrittingerOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT00432107 | A Study to Assess APO866 for the Treatment of Advanced Melanoma | completed | Phase 2 | 25 | Valerio TherapeuticsINDUSTRY | 4 | Sep 29, 2015 | clinicaltrials |
| NCT00791778 | Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer | completed | Phase 2 | 246 | BayerINDUSTRY | 14 | Sep 28, 2015 | clinicaltrials |
| NCT00324779 | Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia | completed | Phase 2 | 79 | University Hospital ErlangenOTHER | 2 | Sep 25, 2015 | clinicaltrials |
| NCT02502968 | BL-8040 Addition to Consolidation Therapy in AML Patients(BLAST) | unknown | Phase 2 | 194 | Dr. Petra TschanterOTHER | 1 | Sep 21, 2015 | clinicaltrials |
| NCT02480010 | A Study of Pertuzumab in Participants With Prostate Cancer | terminated | Phase 2 | 68 | Hoffmann-La RocheINDUSTRY | 6 | Sep 18, 2015 | clinicaltrials |
| NCT00632749 | BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment | completed | Phase 2 | 68 | Boehringer IngelheimINDUSTRY | 1 | Sep 14, 2015 | clinicaltrials |
| NCT00786994 | The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses | completed | Phase 2 | 165 | Birken AGINDUSTRY | 2 | Sep 14, 2015 | clinicaltrials |
| NCT00318370 | Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy | completed | Phase 2 | 58 | MorphotekINDUSTRY | 2 | Sep 9, 2015 | clinicaltrials |
| NCT00570713 | An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer | completed | Phase 2 | 155 | MorphotekINDUSTRY | 5 | Sep 9, 2015 | clinicaltrials |
| NCT01441596 | Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases | completed | Phase 2 | 121 | Boehringer IngelheimINDUSTRY | 8 | Sep 7, 2015 | clinicaltrials |
| NCT01236391 | Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)(PCYC-1104-CA) | completed | Phase 2 | 115 | Pharmacyclics LLC.INDUSTRY | 4 | Aug 28, 2015 | clinicaltrials |
| NCT02491892 | A Study of Pertuzumab in Participants With Metastatic Breast Cancer | completed | Phase 2 | 79 | Hoffmann-La RocheINDUSTRY | 8 | Aug 25, 2015 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials